Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21

Gastroenterology

Volumn 141, Issue 4, 2011, Pages

  Huang, Yuehua ^a   Tong, Shuping ^b   Tai, Andrew W ^a,c   Hussain, Munira ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BROWN UNIVERSITY   (United States)

^c Ann Arbor Veterans Administration Health System   (United States)

Author keywords

Genetics; Liver Cancer; Tumorigenesis; Virology

Indexed keywords

ALANINE; CYCLIN E; PROTEIN P21; S PHASE KINASE ASSOCIATED PROTEIN 2; THREONINE; UBIQUITIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL LINE; CELL PROLIFERATION; CELL STRAIN HEPG2; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; VIRUS GENE; WILD TYPE;

EID: 80053583197     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.06.048     Document Type: Article

References (47)

1. H.I. Yang, S.N. Lu, and Y.F. Liaw Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 2002 168 174
2. M.F. Yuen, Y. Tanaka, and N. Shinkai Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels Gut 57 2008 98 102
3. H.I. Yang, S.H. Yeh, and P.J. Chen Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma J Natl Cancer Inst 100 2008 1134 1143
4. C.J. Chen, H.I. Yang, and J. Su Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73 (Pubitemid 43042691)
5. S. Liu, H. Zhang, and C. Gu Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis J Natl Cancer Inst 101 2009 1066 1082
6. X. Guo, Y. Jin, and G. Qian Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China J Hepatol 49 2008 718 725
7. Y.C. Chou, M.W. Yu, and C.F. Wu Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma Gut 57 2008 91 97
8. S.Y. Kuang, P.E. Jackson, and J.B. Wang Specific mutations of hepatitis B virus in plasma predict liver cancer development Proc Natl Acad Sci U S A 101 2004 3575 3580 (Pubitemid 38338237)
9. K. Ito, Y. Tanaka, and M. Kato Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion J Gastroenterol 42 2007 837 844 (Pubitemid 47617462)
10. S. Parekh, F. Zoulim, and S.H. Ahn Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants J Virol 77 2003 6601 6612 (Pubitemid 36666854)
11. V.E. Buckwold, Z. Xu, and M. Chen Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication J Virol 70 1996 5845 5851 (Pubitemid 26266795)
12. C.J. Chu, E.B. Keeffe, and S.H. Han Prevalence of HBV precore/core promoter variants in the United States Hepatology 38 2003 619 628 (Pubitemid 37055449)
13. Z.L. Fang, C.A. Sabin, and B.Q. Dong The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis J Hepatol 50 2009 273 280
14. Y.K. Chun, J.Y. Kim, and H.J. Woo No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection Hepatology 32 2000 1154 1162
15. M.J. Bouchard, and R.J. Schneider The enigmatic X gene of hepatitis B virus J Virol 78 2004 12725 12734 (Pubitemid 39507781)
16. Z. Hu, Z. Zhang, and E. Doo Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex J Virol 73 1999 7231 7240 (Pubitemid 29383204)
17. Y. Wang, M. Reed, and P. Wang p53 domains: identification and characterization of two autonomous DNA-binding regions Genes Dev 7 1993 2575 2586 (Pubitemid 24021014)
18. Y. Lin, T. Nomura, and T. Yamashita The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct Cancer Res 57 1997 5137 5142 (Pubitemid 27498132)
19. S.S. Thorgeirsson, and J.W. Grisham Molecular pathogenesis of human hepatocellular carcinoma Nat Genet 31 2002 339 346 (Pubitemid 35154440)
20. C.J. Sherr, and J.M. Roberts CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev 13 1999 1501 1512 (Pubitemid 29297917)
21. Y. Xiong, G.J. Hannon, and H. Zhang p21 is a universal inhibitor of cyclin kinases Nature 366 1993 701 704 (Pubitemid 24036020)
22. J. Bartek, and J. Lukas DNA damage checkpoints: from initiation to recovery or adaptation Curr Opin Cell Biol 19 2007 238 245 (Pubitemid 46386406)
23. J. Martin-Caballero, J.M. Flores, and P. Garcia-Palencia Tumor susceptibility of p21(Waf1/Cip1)-deficient mice Cancer Res 61 2001 6234 6238
24. A.J. Poole, D. Heap, and R.E. Carroll Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon Oncogene 23 2004 8128 8134 (Pubitemid 39531853)
25. W. Yang, A. Velcich, and I. Lozonschi Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice Am J Pathol 166 2005 1239 1246 (Pubitemid 40524446)
26. A. Carnero, and D.H. Beach Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation Oncogene 23 2004 6006 6011 (Pubitemid 39093546)
27. L. Qiao, K. Leach, and R. McKinstry Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression Hepatology 34 2001 906 917 (Pubitemid 33032025)
28. U.S. Park, S.K. Park, and Y.I. Lee Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1→S transition via a p53-independent pathway in human hepatoma cells Oncogene 19 2000 3384 3394 (Pubitemid 30479333)
29. H.J. Kwun, and K.L. Jang Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene Nucleic Acids Res 32 2004 2202 2213 (Pubitemid 38854774)
30. D. Frescas, and M. Pagano Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer Nat Rev Cancer 8 2008 438 449 (Pubitemid 351744963)
31. D. Hoeller, and I. Dikic Targeting the ubiquitin system in cancer therapy Nature 458 2009 438 444
32. G. Bornstein, J. Bloom, and D. Sitry-Shevah Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase J Biol Chem 278 2003 25752 25757 (Pubitemid 36835332)
33. T. Krude Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state J Biol Chem 275 2000 13699 13707 (Pubitemid 30257440)
34. T. Abbas, and A. Dutta p21 in cancer: intricate networks and multiple activities Nat Rev Cancer 9 2009 400 414
35. A. Teufel, T. Maass, and S. Strand Liver-specific Ldb1 deletion results in enhanced liver cancer development J Hepatol 53 2010 1078 1084
36. N. Charette, C. De Saeger, and V. Lannoy Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition Mol Cancer 9 2010 256 269
37. S. Senturk, M. Mumcuoglu, and O. Gursoy-Yuzugullu Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth Hepatology 52 2010 966 974
38. D. Gao, H. Inuzuka, and A. Tseng Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction Nat Cell Biol 11 2009 397 408
39. D.F. Calvisi, S. Ladu, and F. Pinna SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis Gastroenterology 137 2009 1816 1826
40. W.S. el-Deiry, T. Tokino, and V.E. Velculescu WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825 (Pubitemid 23346378)
41. S.D. Boyd, K.Y. Tsai, and T. Jacks An intact HDM2 RING-finger domain is required for nuclear exclusion of p53 Nat Cell Biol 2 2000 563 568
42. B.P. Zhou, Y. Liao, and W. Xia Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells Nat Cell Biol 3 2001 245 252 (Pubitemid 32201319)
43. S.C. Strom, L.A. Pisarov, and K. Dorko Use of human hepatocytes to study P450 gene induction Methods Enzymol 272 1996 388 401 (Pubitemid 26299903)
44. S.M. Zamule, S.C. Strom, and C.J. Omiecinski Preservation of hepatic phenotype in lentiviral-transduced primary human hepatocytes Chem Biol Interact 173 2008 179 186
45. L. Jouan, P. Melancon, and I.G. Rodrigue-Gervais Distinct antiviral signaling pathways in primary human hepatocytes and their differential disruption by HCV NS3 protease J Hepatol 52 2010 167 175
46. S.N. Wong, K.R. Reddy, and E.B. Keeffe Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma Liver Transpl 13 2007 334 342 (Pubitemid 46444461)
47. R. Pang, T.K. Lee, and R.T. Poon Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis Gastroenterology 132 2007 1088 1103 (Pubitemid 46440863)